The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Visual and standardized uptake values assessment of lesions and biodistribution
研究概览
简要总结
Here's a polished version of the text:
"This project involves patients with high-expression LRRC15 malignant tumors who are either clinically suspected of or diagnosed with pancreatic cancer, breast cancer, lung cancer, ovarian cancer, head and neck tumors, colorectal cancer, melanoma, etc., as well as healthy volunteers. Using a targeted LRRC15-specific SPECT imaging agent, SPECT/CT imaging is performed to achieve the following objectives:
For malignant tumor patients:
To support disease diagnosis and staging. Diagnostic performance will be evaluated against the gold standard of pathological diagnosis, clarifying the presence or absence of lesions and determining their location and nature.
To enable accurate staging and assess tumor burden by comparison with [18F]FDG PET/CT, thereby aiding in the determination of treatment plans.
For healthy volunteers:
To conduct pharmacokinetic analysis, elucidating the distribution, metabolism, and safety profile of the agent in the body."
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Each subject must meet all of the following inclusion criteria to be eligible for study enrollment:
- •The subject or their legally authorized representative (LAR) is capable of providing a signed and dated informed consent form (ICF);
- •Willing and able to comply with all study procedures and cooperate throughout the entire duration of the study;
- •Adult patients or healthy volunteers, aged 18 years or older, male or female;
- •Patients with clinically suspected or confirmed malignancies (supported by evidence such as relevant serum tumor markers, imaging modalities including ultrasound, CT, and MRI, or histopathological examinations) who are in good general condition;
- •Women of childbearing potential (WOCBP) must have used effective contraception for at least one month prior to screening and agree to continue contraceptive use throughout the study period and for a specified duration following study completion;
- •Must meet any other protocol-specified inclusion criteria.
排除标准
- •Any subject meeting any of the following baseline criteria will be excluded from the study:
- •Inability to tolerate or complete SPECT/CT examinations (including, but not limited to, the inability to lie supine, claustrophobia, radiophobia, etc.);
- •Presence of other comorbidities, such as acute systemic illnesses and electrolyte imbalances;
- •Known allergy or hypersensitivity to the LRRC15 radiotracer or its synthetic excipients; fasting blood glucose level exceeding 11.0 mmol/L prior to [¹⁸F]FDG injection;
- •Patients deemed by the investigator to have poor expected compliance;
- •Pregnant or lactating (nursing) women;
- •Presence of any other conditions or factors that, in the opinion of the investigator, would make the subject unsuitable for participation in this trial.
结局指标
主要结局
Visual and standardized uptake values assessment of lesions and biodistribution
时间窗: 1 year
At least two experienced nuclear medicine physicians will conduct a visual analysis using consensus reading. The standardized uptake value (SUV) of the tumor and organs will be measured after a semiquantitative analysis is performed for each case. The SUV ranges from 0 to infinity, and a higher score means a higher uptake of targeting LRRC15 nuclear probe by the tumor, which implies a greater threat of the tumor being malignant or a higher stage.
次要结局
未报告次要终点